Stock Track | NeoGenomics Plummets 12.34% as Q4 Results Miss Estimates, Guidance Disappoints

Stock Track

Feb 18, 2025

NeoGenomics (NEO), a leading oncology testing services company, experienced a significant plummet of 12.34% in pre-market trading on Tuesday, February 18, 2025, after reporting its fourth-quarter and full-year 2024 results.

The company's fourth-quarter revenue of $172 million fell short of Wall Street's expectations of $173.2 million, despite a year-over-year increase of 11%. NeoGenomics also missed analyst estimates for its fourth-quarter earnings, reporting an adjusted earnings per share (EPS) of $0.04, slightly above the consensus estimate of $0.03.

However, the more significant factor contributing to the stock's plummet was the company's full-year 2025 guidance, which failed to meet investor expectations. While NeoGenomics reaffirmed its revenue guidance range of $735 million to $745 million for 2025, representing growth of 11% to 13% year-over-year, the midpoint of $740 million was only 0.7% above analysts' estimates. Furthermore, the company's adjusted EPS guidance range of $0.15 to $0.19 for 2025 disappointed investors, with the midpoint of $0.17 falling short of the consensus estimate of $0.20.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1124200139"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124200139\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124200139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-18 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124200139","market":"hk","top_or_hot":-1,"title":"Stock Track | NeoGenomics Plummets 12.34% as Q4 Results Miss Estimates, Guidance Disappoints","media":"Stock Track","content":"<p>NeoGenomics (NEO), a leading oncology testing services company, experienced a significant plummet of 12.34% in pre-market trading on Tuesday, February 18, 2025, after reporting its fourth-quarter and full-year 2024 results.</p>\n\n<p>The company's fourth-quarter revenue of $172 million fell short of Wall Street's expectations of $173.2 million, despite a year-over-year increase of 11%. NeoGenomics also missed analyst estimates for its fourth-quarter earnings, reporting an adjusted earnings per share (EPS) of $0.04, slightly above the consensus estimate of $0.03.</p>\n\n<p>However, the more significant factor contributing to the stock's plummet was the company's full-year 2025 guidance, which failed to meet investor expectations. While NeoGenomics reaffirmed its revenue guidance range of $735 million to $745 million for 2025, representing growth of 11% to 13% year-over-year, the midpoint of $740 million was only 0.7% above analysts' estimates. Furthermore, the company's adjusted EPS guidance range of $0.15 to $0.19 for 2025 disappointed investors, with the midpoint of $0.17 falling short of the consensus estimate of $0.20.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NeoGenomics Plummets 12.34% as Q4 Results Miss Estimates, Guidance Disappoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NeoGenomics Plummets 12.34% as Q4 Results Miss Estimates, Guidance Disappoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-18 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NeoGenomics (NEO), a leading oncology testing services company, experienced a significant plummet of 12.34% in pre-market trading on Tuesday, February 18, 2025, after reporting its fourth-quarter and full-year 2024 results.</p>\n\n<p>The company's fourth-quarter revenue of $172 million fell short of Wall Street's expectations of $173.2 million, despite a year-over-year increase of 11%. NeoGenomics also missed analyst estimates for its fourth-quarter earnings, reporting an adjusted earnings per share (EPS) of $0.04, slightly above the consensus estimate of $0.03.</p>\n\n<p>However, the more significant factor contributing to the stock's plummet was the company's full-year 2025 guidance, which failed to meet investor expectations. While NeoGenomics reaffirmed its revenue guidance range of $735 million to $745 million for 2025, representing growth of 11% to 13% year-over-year, the midpoint of $740 million was only 0.7% above analysts' estimates. Furthermore, the company's adjusted EPS guidance range of $0.15 to $0.19 for 2025 disappointed investors, with the midpoint of $0.17 falling short of the consensus estimate of $0.20.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEO","symbol_name":"NeoGenomics","start_time":0,"source_url":"","article_id":"1124200139","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124200139","pubTimestamp":1739889199,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NeoGenomics , a leading oncology testing services company, experienced a significant plummet of 12.34% in pre-market trading on Tuesday, February 18, 2025, after reporting its fourth-quarter and full-year 2024 results.The company's fourth-quarter revenue of $172 million fell short of Wall Street's expectations of $173.2 million, despite a year-over-year increase of 11%. NeoGenomics also missed analyst estimates for its fourth-quarter earnings, reporting an adjusted earnings per share  of $0.04, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEO":"NeoGenomics"},"translate_title":"股票赛道NeoGenomics暴跌12.34%，第四季度业绩未达预期，指引令人失望","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":1},"content_text":"NeoGenomics (NEO), a leading oncology testing services company, experienced a significant plummet of 12.34% in pre-market trading on Tuesday, February 18, 2025, after reporting its fourth-quarter and full-year 2024 results.\nThe company's fourth-quarter revenue of $172 million fell short of Wall Street's expectations of $173.2 million, despite a year-over-year increase of 11%. NeoGenomics also missed analyst estimates for its fourth-quarter earnings, reporting an adjusted earnings per share (EPS) of $0.04, slightly above the consensus estimate of $0.03.\nHowever, the more significant factor contributing to the stock's plummet was the company's full-year 2025 guidance, which failed to meet investor expectations. While NeoGenomics reaffirmed its revenue guidance range of $735 million to $745 million for 2025, representing growth of 11% to 13% year-over-year, the midpoint of $740 million was only 0.7% above analysts' estimates. Furthermore, the company's adjusted EPS guidance range of $0.15 to $0.19 for 2025 disappointed investors, with the midpoint of $0.17 falling short of the consensus estimate of $0.20.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}